iCo IND accepted

Article

The FDA has accepted iCoTherapeutics' Investigational New Drug (IND) application for iCo-007.

The FDA has accepted iCoTherapeutics' Investigational New Drug (IND) application for iCo-007, a treatment for diabetic macular oedema (DME).

iCo-007 is a second generation antisense compound that targets c-Raf kinase messenger RNA and reduces the oedema by decreasing the signalling of growth factors such as VEGF that signal through the c-Raf kinase pathway.

Related Videos
Josefina Botta, MD, MSc, at ASCRS 2024
Dr Nir Shoham Hazon, Director, Miramichi EyeNB Centre of Excellence, New Brunswick, Canada
J. Morgan Micheletti, MD, speaks at the 2024 ASCRS meeting
Dr William Wiley of Cleveland Eye Clinic, Northeast Ohio
© 2024 MJH Life Sciences

All rights reserved.